ClinicalTrials.gg
Status unknownNCT03863002Updated Mar 20, 2019

Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure

A Phase 1/2 interventional study of Mesenchymal Stem Cell in Liver Failure, Acute on Chronic, sponsored by Tianjin Weikai Bioeng., Ltd.. Status unknown at 1 site in China. Open to participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-03-20.

Sponsored by Tianjin Weikai Bioeng., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
16 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Acute-On-Chronic Liver Failure with a site in China — 18 open to participants now, 22 under way, none of them phase 3. Acute-On-Chronic Liver Failure · China.

Planned enrollment
16th of 25
45 · median 80
Started
2019
with 8 others
Phase 1/2
4 of 48
1 open now
Registered
12th of 48
by date

Among the 48 studies in Acute-On-Chronic Liver Failure with a site in China, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is one of 9 that started in 2019, is one of 4 in phase 1/2, and was the 12th registered.

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

Browse Acute-On-Chronic Liver Failure studies →

Open to participants now

18 of the 48 studies in Acute-On-Chronic Liver Failure with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Acute-On-Chronic Liver Failure studies recruiting now, 11 (35%) set no upper age limit and 14 (45%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 16 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Acute-On-Chronic Liver Failure with a site in China, or all of them as a file.
02

Study summary

Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure

Read the detailed description

Acute-on-chronic liver failure (ACLF) which occurs in patients with chronic liver disease, is a serious live-threatening disease. Currently, the clinical management, such as liver protection, anti-virus medicine, and artificial liver support, has not significantly improve the outcomes, the mortality still remains over 50%. Liver transplantation is the only effective treatment of ACLF, but this therapy is limited by the shortage of donor organs, potential surgical complications, immunological rejection and high medical costs. Mesenchymal stem cell (MSC) is one of adult stem cells, which has been suggested to play a role in amelioration of liver disease, such as: trans-differentiation of MSCs into hepatocytes, immunomodulation, inhibition of fibrosis development, protective effects on hepatic cell and restoration of hepatic cell proliferation capacity.

03

Conditions studied

  • Liver Failure, Acute on Chronic

Keywords

  • mesenchymal stem cell
04

Who can participate

Ages eligible
16 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meeting the definition of ACLF: patients with previously diagnosed or undiagnosed chronic liver disease acute decompensated within 4 weeks; significant GI symptom as such fatigue, jaundice; serum total [TBil] ≥10 X the ; coagulopathy ( [INR] ≥1.5 or prothrombin activity [PTA] \<40%); complicated within 4 weeks by ascites and/or encephalopathy as determined by physical examination.
  2. Model for End-Stage Liver Disease (MELD) scores ranging 17-30, (MELD(i) = 0.957 × ln(Cr) + 0.378 × ln(bilirubin) + 1.120 × ln(INR) + 0.643);
  3. Chronic liver disease with definitive etiology such as viral hepatitis, alcohol liver disease, drug induced liver injury or liver diseases
  4. Body weight ≥50kg

Exclusion criteria

Exclusion Criteria:

  1. Serious complications in the previous 2 months (e.g., gastrointestinal bleeding: below 90g/L, serious infection such as sepsis, ascites ultrafiltration, and/or dialysis);
  2. Malignant jaundice induced by obstructive jaundice or hemolytic jaundice;
  3. Hepatocellular carcinoma (HCC) diagnosed by radiologic imaging and/or alpha fetoprotein (AFP);
  4. Tumor diagnosed by ultrasound, CT, MR examination;
  5. Moderate or severe chronic heart failure ( III-IV), renal replacement therapy, severe chronic pulmonary disease (GOLD III-IV)
  6. Extrahepatic cholestasis
  7. Hepatic, portal and splenic vein thrombosis diagnosed by doppler ultrasound
  8. Artificial liver support
  9. Previous liver transplantation
  10. Drug abuse in the past 5 years;
  11. Mental disorders and/or has a family history of mental disorder.
  12. infection
  13. Pregnant or breast-feeding females
  14. Highly allergic
  15. Patients can not cooperate or mobility
  16. Enrolled in other clinical trials with 3 months
  17. Patients who can not provide prior or refusal to participate
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • No intervention
    Standard Medical Treatment

    Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin \<30 g/L), fresh frozen plasma (200-400 mL/day until the INR was \<1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome \[HRS\]).

  • Experimental
    Mesenchymal Stem Cell

    Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10\^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT.

    Biological: Mesenchymal Stem Cell

Interventions

  • Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10\^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks

06

What researchers measure

Primary outcomes

  1. survival rate

    Number of participants alive

    Time frame: 72 weeks after treatment

Secondary outcomes

  1. Adverse reactions

    Number of participants with adverse reactions (e.g. fever, rash, and diarrhea )

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  2. White blood cell

    Change of white blood cell count

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  3. Platelet

    Change of platelet count

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  4. Hemoglobin

    Change of hemoglobin level

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  5. Creatinine

    Change of creatinine level as a surrogate marker of liver function

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  6. ALT

    Change of alanine aminotransferase (ALT) level as a marker of liver function

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  7. ALB

    Change of albumin (ALB) level as a maker of liver function

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  8. TBil

    Change of total Bilirubin (TBil) level as a marker of liver function

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  9. INRs

    Change of international normalized ratio (INRs) level as a marker of liver function

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  10. AFP

    Change of alpha fetoprotein (AFP) level as a marker of liver function

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  11. MELD scores

    Model for End-Stage Liver Disease (MELD) score for assessing the severity of chronic liver disease is measured as absolute change to baseline score

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  12. Tumor formation

    Number of participants with hepatocellular carcinoma or extrahepatic malignant tumors

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

  13. Liver failure-associated serious complications

    Number of participants with liver failure-associated serious complications, such as infections, encephalopathy, gastrointestinal bleeding and HRS

    Time frame: Week 1, 2, 4, 8, 12, 24, 36, 48

07

Study locations

1 site
  • Tianjin Weikai Bioeng., Ltd.
    Tianjin, Tianjin, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2019; primary completion for Oct 2021, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2019
First posted
Mar 5, 2019
StartEst.
Oct 1, 2019
Primary completionEst.
Oct 1, 2021
CompletionEst.
Oct 1, 2022
Last update
Mar 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03863002
Lead sponsor
Tianjin Weikai Bioeng., Ltd.
Collaborators
Tianjin Nankai Hospital
Responsible party
Sponsor
First posted
Mar 5, 2019
Start date
Oct 1, 2019 (estimated)
Primary completion
Oct 1, 2021 (estimated)
Completion
Oct 1, 2022 (estimated)
Last update
Mar 20, 2019

Study contacts

Xiuli Cong, MD, PhD
Contact
cong_xiuli@163.com
+86 18512507567

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesenchymal Stem Cell

Start the discussion